Altering the Human Prostate Tumor Immune Microenvironment Through Inhibition of Ibrutinib

Time: 2:45 pm
day: Pre-Conference Focus Day


  • This is the first clinical trial of the BTK inhibitor ibrutinib in prostate cancer
  • Ibrutinib may alter favorably alter the prostate tumor microenvironment by
    reducing pro-tumor B cells and increasing anti-tumor T cells
  • Inhibition of BTK may also limit tumor cell-intrinsic growth
  • Prostate tissue and peripheral correlative studies will be performed to evaluate
    the further use of ibrutinib in prostate cancer